"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
| Descriptor ID |
D020533
|
| MeSH Number(s) |
D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
|
| Concept/Terms |
Angiogenesis Inhibitors- Angiogenesis Inhibitors
- Neovascularization Inhibitors
- Angiogenic Antagonists
- Angiogenic Inhibitors
- Angiostatic Agents
- Agents, Angiostatic
- Antagonists, Angiogenic
- Anti-Angiogenetic Agents
- Agents, Anti-Angiogenetic
- Anti Angiogenetic Agents
- Anti-Angiogenic Drugs
- Anti Angiogenic Drugs
- Drugs, Anti-Angiogenic
- Antiangiogenic Agents
- Agents, Antiangiogenic
- Inhibitors, Angiogenesis
- Inhibitors, Angiogenetic
- Inhibitors, Angiogenic
- Inhibitors, Neovascularization
- Angiogenetic Antagonists
- Antagonists, Angiogenetic
- Angiogenetic Inhibitors
Anti-Angiogenesis Effect- Anti-Angiogenesis Effect
- Anti Angiogenesis Effect
- Effect, Anti-Angiogenesis
- Antiangiogenesis Effect
- Effect, Antiangiogenesis
- Antiangiogenesis Effects
- Effects, Antiangiogenesis
- Anti-Angiogenesis Effects
- Anti Angiogenesis Effects
- Effects, Anti-Angiogenesis
|
Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".
This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 2 | 4 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 3 | 5 |
| 2012 | 3 | 3 | 6 |
| 2013 | 2 | 2 | 4 |
| 2014 | 4 | 3 | 7 |
| 2015 | 7 | 1 | 8 |
| 2016 | 5 | 1 | 6 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 3 | 2 | 5 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 3 | 5 |
| 2022 | 2 | 1 | 3 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 3 | 6 |
| 2025 | 2 | 1 | 3 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.
-
Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction. JAMA Ophthalmol. 2026 05 01; 144(5):415-422.
-
Development of Miniprotein Binders to Inhibit VEGF-Induced Corneal Neovascularization. Invest Ophthalmol Vis Sci. 2026 05 01; 67(5):61.
-
Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study. Ophthalmology. 2026 Jul; 133(7):837-851.
-
Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatment. Eye (Lond). 2025 Dec; 39(17):3045-3057.
-
Short-term effects of tetracycline use in patients with diabetic retinopathy. Can J Ophthalmol. 2025 12; 60(6):e858-e868.
-
Use of Home Optical Coherence Tomography for Retinal Diseases. Int Ophthalmol Clin. 2025 Jan 01; 65(1):41-46.
-
Therapies for Central Serous Chorioretinopathy: A Report by the American Academy of Ophthalmology. Ophthalmology. 2025 03; 132(3):343-353.
-
Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy. Int J Mol Sci. 2024 Sep 01; 25(17).
-
International Classification System for Ocular Complications of Anti-VEGF Agents in Clinical Trials. Ophthalmology. 2024 12; 131(12):1457-1467.
-
Healthcare Spending and Systemic Bevacizumab for Recurrent Respiratory Papillomatosis. J Voice. 2026 Sep; 40(5):1488-1493.